Earnings ·
Aardvark Therapeutics reported second quarter 2026 financial results, including a net loss of $14.4 million and cash…
AARDAardvark Therapeutics, Inc.
Aardvark Therapeutics reported second quarter 2026 financial results, including a net loss of $14.4 million and cash reserves of $73.9 million sufficient to fund operations into late 2027. The company terminated its Phase 3 HERO and Open Label Extension trials for ARD-101 in June 2026 following a full clinical hold placed by the FDA in May 2026. Aardvark plans to assess unblinded data from these trials in the third quarter of 2026 to determine next steps while maintaining active discussions with regulators regarding the clinical hold.